Anti-IL32 antibody

Anti-IL32 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit polyclonal to IL32

ELISA, WB

Human IL32

IL32 antibody; IL-32 alpha antibody; IL-32beta antibody; IL-32delta antibody; IL-32gamma antibody; NK4 antibody; TAIF antibody; TAIFa antibody; TAIFb antibody; TAIFc antibody; TAIFd antibody

Rabbit IgG

Produced in rabbits immunized with purified, recombinant Human IL32 (rh IL32; NP_001012651.1; Met1-Lys131). IL32 specific IgG was purified by Human IL32 affinity chromatography.

Polyclonal

0.2 μm filtered solution in PBS

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

IL-32 is a recently discovered cytokine that induces various proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and chemokines in both human and mouse cells through the NF-kappaB and p38 MAPK inflammatory signal pathways. It is regulated robustly by other major proinflammatory cytokines, and is crucial to inflammation and immune responses. Four of the IL-32 isoforms (alpha, beta, gamma and delta) are the most representative IL-32 transcripts, and gamma isoform of IL-32 is the most active, although all isoforms are biologically active. IL-32, a cytokine produced mainly by T, natural killer, and epithelial cells induces significant amounts of TNFalpha and MIP-2 and increases the production of both cytokines in a dose-dependent manner. IL-32 has been implicated in inflammatory disorders, mycobacterium tuberculosis infections, inflammatory bowel disease, and influenza A virus infection, as well as in some autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis and in human stomach cancer, human lung cancer and breast cancer tissues. Thus, IL-32 expression might be valuable as a biomarker for cancer.

• Felaco P, et al. (2009) IL-32: a newly-discovered proinflammatory cytokine. J Biol Regul Homeost Agents. 23(3): 141-7.
• Kobayashi H, et al. (2009) Molecular characterization of IL-32 in human endothelial cells. Cytokine. 46(3): 351-8.
• Meyer N, et al. (2010) IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol. 125(4): 858-865.